MPPE1 and neoplasm: This was described for the occurrence of secondary resistance in mice treated with the combination therapy α-CTLA-4 and αPD-1, after cDC1 anti-cancer vaccination and after combined treatment with CPI and an anti-tumor vaccine [118,119,120].